Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous
Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
대표청구항▼
We claim: 1. A particulate composition for delivery to the pulmonary system, the composition comprising: particles comprising an active agent, a saturated phospholipid and a polyvalent cation, wherein the molar ratio of polyvalent cation to phospholipid is at least 0.05 and is sufficiently high to
We claim: 1. A particulate composition for delivery to the pulmonary system, the composition comprising: particles comprising an active agent, a saturated phospholipid and a polyvalent cation, wherein the molar ratio of polyvalent cation to phospholipid is at least 0.05 and is sufficiently high to increase the gel-to-liquid crystal transition temperature of the particles compared to particles without the polyvalent cation such that the particles have a gel-to-liquid crystal transition temperature that is greater than room temperature by at least 20�� C. 2. A particulate composition according to claim 1 wherein said gel-to-liquid crystal transition temperature is greater than room temperature by at least 40�� C. 3. A particulate composition according to claim 1 further comprising a surfactant selected from the group consisting of nonionic detergents, nonionic block copolymers, ionic surfactants and combinations thereof. 4. A particulate composition according to claim 3 wherein the surfactant is selected from the group consisting of sorbitan esters, ethoxylated sorbitan esters, fatty acids, salts, sugar esters, ethylene oxides, and combinations thereof. 5. A particulate composition according to claim 1 wherein the polyvalent cation is a divalent cation. 6. A particulate composition according to claim 5 wherein the divalent cation is selected from the group consisting of calcium, magnesium and zinc. 7. A particulate composition according to claim 5 wherein the molar ratio of divalent cation to phospholipid is 0.05-2.0. 8. A particulate composition according to claim 5 wherein the molar ratio of divalent cation to phospholipid is 0.25-1.0. 9. A particulate composition according to claim 8 wherein the divalent cation is calcium. 10. A particulate composition according to claim 9 wherein the molar ratio of calcium to phospholipid is about 0.50. 11. A particulate composition according to claim 1 wherein the phospholipid comprises a natural or synthetic lung surfactant. 12. A particulate composition according to claim 1 wherein the active agent is selected from the group consisting of nicotine, human growth hormone, parathyroid hormone, leuprolide, budesonide, tobramycin, albuterol, insulin, interferon alpha, interferon beta, amphotericin, fluticasone, salmeterol, formoterol, and salts thereof. 13. A particulate composition according to claim 1 further comprising a polymer selected from the group consisting of polysaccharides, polyvinyl alcohol, polyvinyl pyrrolidone, polylactides, polyglycolides, polyethylene glycol, and mixtures thereof. 14. A particulate composition according to claim 1 comprising particles having a mass median diameter of less than 20 microns. 15. A particulate composition according to claim 14 wherein the mass median diameter is within 0.5-5 microns. 16. A particulate composition according to claim 14 wherein the particles comprise an aerodynamic diameter of less than 10 microns. 17. A particulate composition according to claim 16 wherein the aerodynamic diameter is within 0.5-5 microns. 18. A particulate composition according to claim 1 comprising an emitted dose of at least 40%. 19. A particulate composition according to claim 1 comprising an emitted dose of at least 60%. 20. A particulate composition according to claim 1 comprising an emitted dose of at least 90%. 21. A particulate composition according to claim 1 further comprising a non-aqueous suspension medium. 22. A particulate composition according to claim 1 further comprising an excipient selected from the group consisting of amino acids, carbohydrates, inorganic salts, organic salts, carboxylic acids, and mixtures thereof. 23. A particulate composition according to claim 22 wherein the excipient is selected from the group consisting of hydrophobic amino acids, monosaccharides, disaccharides, polysaccharides, sodium citrate, citric acid, ammonium carbonate, ammonium acetate, and ammonium chloride. 24. A particulate composition according to claim 1 wherein the bulk density of the particulate composition is less than 0.5 g/cm3. 25. A particulate composition according to claim 24 wherein the bulk density of the particulate composition is less than 0.05 g/cm3. 26. A particulate composition comprising: particles comprising an active agent, a saturated phospholipid and a polyvalent cation, wherein the molar ratio of polyvalent cation to phospholipid is at least 0.05 and wherein the particles have a gel-to-liquid transition temperature at least 20�� C. higher than room temperature. 27. A particulate composition for delivery to the pulmonary system, the composition comprising porous particles comprising: 20-99.9% of a saturated phospholipid; a polyvalent cation; and 0.1-80% active agent; wherein the molar ratio of polyvalent cation to phospholipid is at least 0.05 and is sufficiently high to increase the gel-to-liquid crystal transition temperature of the particles compared to particles without the polyvalent cation such that the particles have a gel-to-liquid crystal transition temperature that is greater than room temperature by at least 20�� C. 28. A method of delivering an active agent to a patient in need thereof, the method comprising: administering to the respiratory tract of the patient an effective amount of particles comprising an active agent, a saturated phospholipid and a polyvalent cation, wherein the molar ratio of polyvalent cation to phospholipid is at least 0.05 and is sufficiently high to increase the gel-to-liquid crystal transition temperature of the particles compared to particles without the polyvalent cation such that the particles have a gel-to-liquid crystal transition temperature that is greater than room temperature by at least 20�� C. 29. A method according to claim 28 wherein the particulate composition comprises particles having a mass median diameter of less than 20 microns. 30. A method according to claim 29 wherein the mass median diameter is within 0.5-5 microns. 31. A method according to claim 29 wherein the particles comprise an aerodynamic diameter of less than 10 microns. 32. A method according to claim 31 wherein the aerodynamic diameter is within 0.5-5 microns. 33. A method according to claim 28 wherein the particles comprise polyvalent cation at a molar ratio of polyvalent cation:phospholipid of 0.25-1.0. 34. A method according to claim 33 wherein the polyvalent cation comprises calcium. 35. A method according to claim 32 wherein the particles comprise a bulk density of less than 0.5 g/cm3. 36. A method according to claim 35 wherein the active agent is selected from the group consisting of nicotine, human growth hormone, parathyroid hormone, leuprolide, budesonide, tobramycin, albuterol, insulin, interferon alpha, interferon beta, amphotericin, fluticasone, salmeterol, formoterol, and salts thereof. 37. A particulate composition according to claim 1 wherein the particles are hollow and porous. 38. A particulate composition according to claim 1 comprising 0.1-80% w/w of the active agent. 39. A particulate composition according to claim 26 wherein the particles are hollow and porous. 40. A particulate composition according to claim 26 wherein the particles have a gel-to-liquid transition temperature of at least 40�� C. higher than room temperature. 41. A particulate composition according to claim 26 wherein the phospholipid is selected from dipalmitoylphosphatidylcholine or distearoylphosphatidylcholine. 42. A particulate composition comprising: particles comprising a structural matrix comprising a saturated phospholipid and a polyvalent cation, wherein the molar ratio of polyvalent cation to phospholipid is at least 0.05 and is sufficiently high to increase the gel-to-liquid crystal transition temperature of the particles compared to particles without the polyvalent cation such that the particles have a gel-to-liquid crystal transition temperature that is greater than room temperature by at least 20�� C., and wherein the particles further comprise an active agent. 43. A particulate composition according to claim 42 wherein the phospholipid comprises dipalmitoylphosphatidylcholine or distearoylphosphatidylcholine. 44. A particulate composition according to claim 42 wherein the polyvalent cation is a divalent cation. 45. A particulate composition according to claim 44 wherein the divalent cation is selected from the group consisting of calcium, magnesium, and zinc. 46. A particulate composition according to claim 42 wherein the molar ratio of polyvalent cation to phospholipid is 0.05-2.0. 47. A particulate composition according to claim 42 wherein the molar ratio of polyvalent cation to phospholipid is 0.25-1.0. 48. A particulate composition according to claim 42 wherein the active agent is selected from the group consisting of nicotine, human growth hormone, parathyroid hormone, leuprolide, budesonide, tobramycin, albuterol, insulin, interferon alpha, interferon beta, amphotericin, fluticasone, salmeterol, formoterol, and salts thereof. 49. A particulate composition according to claim 44 wherein the divalent cation is calcium. 50. A particulate composition according to claim 49 wherein the molar ratio of calcium to phospholipid is about 0.50. 51. A particulate composition according to claim 42 wherein the particles have a gel-to-liquid crystal transition temperature at least 20�� C. higher than room temperature. 52. A particulate composition according to claim 42 wherein the particles have a gel-to-liquid crystal transition temperature at least 40�� C. higher than room temperature. 53. A particulate composition according to claim 1 wherein the phospholipid is a zwitterionic phospholipid. 54. A particulate composition according to claim 26 wherein the phospholipid is a zwitterionic phospholipid. 55. A particulate composition according to claim 27 wherein the phospholipid is a zwitterionic phospholipid. 56. A particulate composition according to claim 27 wherein the molar ratio of polyvalent cation to phospholipid is effective to increase the gel to liquid crystal transition temperature of the particles compared to particles without the polyvalent cation. 57. A particulate composition according to claim 27 wherein the particles are hollow. 58. A method according to claim 28 wherein the phospholipid is a zwitterionic phospholipid. 59. A particulate composition according to claim 42 wherein the phospholipid is a zwitterionic phospholipid. 60. A particulate composition for delivery to the pulmonary system, the composition comprising: particles comprising an active agent, a saturated phospholipid and a polyvalent cation, wherein the molar ratio of polyvalent cation to phospholipid is at least 0.05 and less than 2, whereby the gel-to-liquid crystal transition temperature of the particles is higher than particles without the polyvalent cation, and is greater than room temperature by at least 20�� C. 61. A particulate composition according to claim 60 wherein the molar ratio of divalent cation to phospholipid is from 0.25 to 1. 62. A particulate composition according to claim 60 wherein the polyvalent cation is a divalent cation. 63. A particulate composition according to claim 62 wherein the divalent cation is selected from the group consisting of calcium, magnesium and zinc. 64. A particulate composition according to claim 62 wherein the divalent cation is calcium. 65. A particulate composition according to claim 64 wherein the molar ratio of calcium to phospholipid is about 0.50. 66. A particulate composition according to claim 60 wherein the gel-to-liquid crystal transition temperature is greater than a storage temperature for the particulate composition by at least 20�� C. 67. A particulate composition according to claim 60 further comprising a surfactant selected from the group consisting of nonionic detergents, nonionic block copolymers, ionic surfactants and combinations thereof. 68. A particulate composition according to claim 60 wherein the particles have a mass median diameter of less than 20 microns and an aerodynamic diameter of less than 10 microns. 69. A particulate composition according to claim 60 further comprising an excipient selected from the group consisting of amino acids, carbohydrates, inorganic salts, organic salts, carboxylic acids, and mixtures thereof. 70. A particulate composition according to claim 60 wherein the bulk density of the particulate composition is less than 0.5 g/cm3. 71. A method of making a temperature stable particulate composition for delivery to the pulmonary system, the method comprising: (a) forming a feedstock comprising a saturated phospholipid emulsion and an active agent; (b) adding a polyvalent cation to the feedstock in an amount sufficient to provide a molar ratio of polyvalent cation to phospholipid in the feedstock that is at least 0.05 and less than 2; and (c) drying the polyvalent cation containing feedstock to form porous particles having a gel-to-liquid crystal transition temperature that is higher than a storage room temperature of the porous particles by at least about 20�� C. 72. A method according to claim 71 wherein (b) comprises adding the polyvalent cation to the feedstock in an amount sufficient to provide a molar ratio of polyvalent cation to phospholipid in the feedstock that is from 0.25 to 1. 73. A method according to claim 71 wherein the polyvalent cation is a divalent cation. 74. A method according to claim 73 wherein the divalent cation is selected from the group consisting of calcium, magnesium and zinc. 75. A method according to claim 73 wherein the divalent cation is calcium. 76. A method according to claim 71 further comprising adding to the feedstock, a surfactant selected comprising nonionic detergents, nonionic block copolymers, ionic surfactants and combinations thereof. 77. A method according to claim 71 further comprising adding to the feedetock a polymer selected from the group consisting of polysaccharides, polyvinyl alcohol, polyvinyl pyrrolidone, polylactides, polyglycolides, polyethylene glycol, and mixtures thereof. 78. A method according to claim 71 comprising drying the polyvalent ion comprising feedstock wherein the particles have a mass median diameter of less than 20 microns and an aerodynamic diameter of less than 10 microns. 79. A method according to claim 71 comprising adding an excipient to the feedstock, the excipient comprising amino acids, carbohydrates, inorganic salts, organic salts, carboxylic acids, and mixtures thereof. 80. A method according to claim 71 comprising drying the polyvalent cation comprising feedstock to provide a bulk density of the porous particles that is less than 0.5 g/cm3.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (128)
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Fu Lu Mou-Ying (Lake Bluff IL) Adjei Akwete L. (Wadsworth IL) Gupta Pramod K. (Gurnee IL), Aerosol drug formulations containing polyglycolyzed glycerides.
Duan Daniel C. (St. Paul MN) Stefely James S. (Woodbury MN) Schultz David W. (Pine Springs MN) Leach Chester L. (Lake Elmo MN), Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid.
Duan Daniel C. ; Stefely James S. ; Schultz David W. ; Leach Chester L., Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing propellant 134a and fluticasone propionate.
Evans Richard M. (Westwood MA) Farr Stephen J. (Llandaf GB7), Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol.
Sekins K. Michael (San Diego CA) Shaffer Thomas H. (Lansdowne PA) Wolfson Marla R. (Wyndmoor PA), Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation.
Bonte Frdric (Boulogne FRX) Dehan Michel (Verrieres le Buisson FRX) Le Ridant Alain (Neuilly sur Seine FRX) Puisieux Francis (Maisons Alfort FRX) Taupin Christiane C. (Orsay FRX), Artificial surfactants, pharmaceutical compositions containing them and use thereof.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann,GB3 ; Taylor Anthony James,GB3 ; Wyatt David Andrew,GB3, Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canisters containing aerosol formulations containing P134a and fluticasone propionate.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Trevino Leo A. (San Diego CA) Dellamary Luis A. (San Marcos CA) Tarara Thomas E. (San Diego CA) Weers Jeffry G. (San Diego CA) Ranney Helen M. (La Jolla CA), Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents.
Illum Lisbeth (Nottingham GBX), Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving mater.
Fuhrman Bradley P. (Buffalo NY) Flaim Stephen F. (San Diego CA) Hernan Lynn J. (Buffalo NY) Nesti Frances D. (Shelburne VT) Papo Michele C. (Buffalo NY) Steinhorn David M. (Eggertsville NY), Fluorocarbons as anti-inflammatory agents.
Byron Peter R. (Richmond) Dalby Richard N. (Richmond VA), Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Byron Peter R. (Richmond VA) Dalby Richard N. (Richmond VA), Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Kaufman Robert J. ; Richard Thomas J. ; Stephens Richard A. ; Goodin Thomas H. ; Allen John S. ; Layton Tony E., Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal.
Cloosterman Aloysius B. M. (Emmerich DEX) Kranenburg Simon V. (Ijssel NLX), Lipid and protein containing material in particulate form and process therefor.
Byron Peter R. (Richmond VA) Blondino Frank E. (Richmond VA), Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable.
Johansson Eric T. ; Ritson Carl ; Rubsamen Reid M., Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissue and controlling their r.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
Greenleaf David J. (Loughborough GB3) Purewal Tarlochan S. (Leamington Spa GB3) Jinks Philip A. (Mount Sorrel GB3), Method for preparing medicinal aerosol formulation containing coated medicament.
Lichtenberger Lenard M. (Houston TX 4), Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy.
Johnson Keith A. (Sunnyvale CA) Gordon Marc S. (Sunnyvale CA) Lyons Shirley W. (Sunnyvale CA), Methods and system for processing dispersible fine powders.
Unger Evan C. ; Fritz Thomas A. ; Matsunaga Terry ; Ramaswami VaradaRajan ; Yellowhair David ; Wu Guanli, Methods of preparing gas and gaseous precursor-filled microspheres.
Egan Edmund A. ; Holm Bruce A. ; Ferguson William H., Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction.
Bernstein Howard (Cambridge MA) Zhang Yan (Cambridge MA) Khan M. Amin (Downingtown PA) Tracy Mark A. (Arlington MA), Modulated release from biocompatible polymers.
Fassberg Julianne (New York NY) Sequeira Joel A. (New York NY) Chaudry Imtiaz A. (North Caldwell NJ) Kopcha Michael (East Brunswick NJ), Non-chlorofluorocarbon aerosol formulations.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Edwards David A. ; Caponetti Giovanni ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Langer Robert S. ; Ben-Jebria Abdellaziz, Porous particles for deep lung delivery.
Sutton Andrew D. (Ruddington GB2) Johnson Richard A. (West Bridgford GB2) Senior Peter J. (Near Melbourne GB2) Heath David (The Park GB2), Preparation of diagnostic agents.
Osborne Nicholas,GBX ; Sutton Andrew Derek,GBX ; Johnson Richard Alan,GBX, Preparation of hollow microcapsules by spray-drying an aqueous solution of a wall-forming material and a water-miscible.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Manning Mark C. ; Randolph Theodore W. ; Shefter Eli ; Falk ; III Richard F., Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the s.
Wong Sui-Ming (Collegeville PA) Newington Ian M. (Hazlemere GB2) Liversidge Elaine M. (West Chester PA) McIntire Gregory L. (West Chester PA) Pitt Alan R. (Sandridge GBX) Shaw Jack M. (Aberdeen MD), Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic delivery systems related applications.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic drug delivery systems.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Schultz Robert K. (Shoreview MN) Quessy Stephen N. (St. Paul MN), Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations.
Vehring, Reinhard; Hartman, Michael Steven; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems.
Vehring, Reinhard; Hartman, Michael Steven; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems.
Vehring, Reinhard; Hartman, Michael Steven; Lechuga-Ballesteros, David; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Jumar, Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents.
Vehring, Reinhard; Hartman, Michael Steven; Lechuga-Ballesteros, David; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions, methods and systems for respiratory delivery of two or more active agents.
Vehring, Reinhard; Hartman, Michael Steven; Lechuga-Ballesteros, David; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions, methods and systems for respiratory delivery of two or more active agents.
Vehring, Reinhard; Hartman, Michael Steven; Lechuga-Ballesteros, David; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions, methods and systems for respiratory delivery of two or more active agents.
Weers, Jeffry G.; Rao, Nagaraja; Huang, Daniel; Miller, Danforth; Tarara, Thomas E., Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases.
Tarara, Thomas E.; Weers, Jeffry G.; Eldon, Michael A.; Narashimhan, Rangachari; Clark, Andrew, Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use.
Tarara, Thomas E.; Weers, Jeffrey G.; Kabalnov, Alexey; Schutt, Ernest G.; Dellamary, Luis A., Pulmonary delivery particles comprising an active agent.
Dellamary, Luis A.; Reiss, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E., Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.